Outcomes of dogs with thymoma treated with intensity modulated stereotactic body radiation therapy or non‐modulated hypofractionated radiation therapy

Abstract

Canine thymomas are routinely treated with radiotherapy (RT). In this study, we investigate the response and toxicity of canine thymoma treated with intensity‐modulated stereotactic body radiation therapy (SBRT) relative to dogs treated with hypofractionated non‐modulated radiation therapy (NMRT). A retrospective study was performed of dogs with thymoma treated with RT (total: n = 15; SBRT: n = 8, NMRT: n = 7). Tumour response was evaluated in six dogs (40%); following SBRT, three dogs (100%) experienced stable disease (SD); following NMRT, one dog (33%) had a PR, and two dogs (67%) had SD. Median PFS was 116 days (range 66–727 days) for the SBRT group and 134 days (range 10–405 days) for the NMRT group. The MST for the SBRT group was 250 days (range 1–727 days) and 155 days (range 10–405 days) for NMRT. Median disease‐specific survival was 250 days (range 1–727 days) for the SBRT group and 169 days (range 20–405 days) for the NMRT group. No significant differences in survival data were found between the treatment groups, however the results from the small number of dogs analysed are likely underpowered for statistical comparisons. Reported acute and late side effects were limited to the lungs and heart and were statistically significantly more common in the NMRT (71%) compared to the SBRT group (25%) (p = .04). We suggest similar treatment efficacy may be provided for canine thymoma treated with either approach, but SBRT could provide the clinical benefit of reduced incidence of radiation‐induced toxicity and completion of RT in a shorter time frame.